ClearPoint Neuro Statistics
Share Statistics
ClearPoint Neuro has 27.98M
shares outstanding. The number of shares has increased by 0.77%
in one year.
| Shares Outstanding | 27.98M |
| Shares Change (YoY) | 0.77% |
| Shares Change (QoQ) | 0.17% |
| Owned by Institutions (%) | 27.56% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 795 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 1.07M, so 3.86% of the outstanding
shares have been sold short.
| Short Interest | 1.07M |
| Short % of Shares Out | 3.86% |
| Short % of Float | 3.97% |
| Short Ratio (days to cover) | 4.21 |
Valuation Ratios
The PE ratio is -21.98 and the forward
PE ratio is -21.74.
ClearPoint Neuro's PEG ratio is
0.99.
| PE Ratio | -21.98 |
| Forward PE | -21.74 |
| PS Ratio | 13.24 |
| Forward PS | 4.5 |
| PB Ratio | 16.37 |
| P/FCF Ratio | -45.06 |
| PEG Ratio | 0.99 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ClearPoint Neuro.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.22,
with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.22 |
| Quick Ratio | 2.56 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $272,956.52 |
| Profits Per Employee | $-164,469.57 |
| Employee Count | 115 |
| Asset Turnover | 0.8 |
| Inventory Turnover | 1.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 96.41% in the
last 52 weeks. The beta is 1.04, so ClearPoint Neuro's
price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | 96.41% |
| 50-Day Moving Average | 12.95 |
| 200-Day Moving Average | 13.23 |
| Relative Strength Index (RSI) | 43.4 |
| Average Volume (20 Days) | 265,576 |
Income Statement
In the last 12 months, ClearPoint Neuro had revenue of 31.39M
and earned -18.91M
in profits. Earnings per share was -0.7.
| Revenue | 31.39M |
| Gross Profit | 19.12M |
| Operating Income | -19.75M |
| Net Income | -18.91M |
| EBITDA | -17.84M |
| EBIT | -19.75M |
| Earnings Per Share (EPS) | -0.7 |
Full Income StatementBalance Sheet
The company has 20.1M in cash and 3.57M in
debt, giving a net cash position of 16.54M.
| Cash & Cash Equivalents | 20.1M |
| Total Debt | 3.57M |
| Net Cash | 16.54M |
| Retained Earnings | -191.37M |
| Total Assets | 39.19M |
| Working Capital | 23.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -8.95M
and capital expenditures -275K, giving a free cash flow of -9.22M.
| Operating Cash Flow | -8.95M |
| Capital Expenditures | -275K |
| Free Cash Flow | -9.22M |
| FCF Per Share | -0.34 |
Full Cash Flow StatementMargins
Gross margin is 60.92%, with operating and profit margins of -62.91% and -60.25%.
| Gross Margin | 60.92% |
| Operating Margin | -62.91% |
| Pretax Margin | -60.25% |
| Profit Margin | -60.25% |
| EBITDA Margin | -56.84% |
| EBIT Margin | -62.91% |
| FCF Margin | -29.39% |
